Business Description
Camp4 Therapeutics Corp
NAICS : 541714
SIC : 2833
ISIN : US13463J1016
Total Employee Number:
48Description
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 36.42 | |||||
Equity-to-Asset | -0.01 | |||||
Debt-to-Equity | -3.42 | |||||
Debt-to-EBITDA | -0.05 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -6.19 | |||||
Beneish M-Score | -3.06 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 23 | |||||
3-Year EPS without NRI Growth Rate | 23.2 | |||||
3-Year FCF Growth Rate | 34.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 34.86 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 44.91 | |||||
9-Day RSI | 52 | |||||
14-Day RSI | 53.46 | |||||
3-1 Month Momentum % | -27.5 | |||||
6-1 Month Momentum % | -26.5 | |||||
12-1 Month Momentum % | 100.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.7 | |||||
Quick Ratio | 4.7 | |||||
Cash Ratio | 4.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -38.6 | |||||
Shareholder Yield % | 1.79 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -1242.51 | |||||
Net Margin % | -2543.74 | |||||
EBITDA Margin % | -1199.27 | |||||
FCF Margin % | -678.15 | |||||
OCF Margin % | -678.15 | |||||
ROE % | -303.69 | |||||
ROA % | -118.02 | |||||
ROIC % | -321.65 | |||||
3-Year ROIIC % | 114.93 | |||||
ROC (Joel Greenblatt) % | -1123.16 | |||||
ROCE % | -67.53 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 50.45 | |||||
EV-to-EBIT | -3.77 | |||||
EV-to-EBITDA | -3.91 | |||||
EV-to-Revenue | 46.9 | |||||
EV-to-FCF | -6.92 | |||||
Earnings Yield (Greenblatt) % | -26.53 | |||||
FCF Yield % | -10.15 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CAMP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Camp4 Therapeutics Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 4.216 | ||
| EPS (TTM) ($) | -2.226 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 131.11 | ||
| 14-Day RSI | 53.46 | ||
| 14-Day ATR ($) | 0.458896 | ||
| 20-Day SMA ($) | 4.2255 | ||
| 12-1 Month Momentum % | 100.63 | ||
| 52-Week Range ($) | 1.41 - 7.75 | ||
| Shares Outstanding (Mil) | 62.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Camp4 Therapeutics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Camp4 Therapeutics Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 76 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | 4.50 (+0.45%) | ||
| General meeting for 2026 | 2026-06-10 11:00 | 4.01 (-1.96%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 4.06 (+2.27%) | ||
| Needham & Company, LLC 25th Annual Healthcare Conference | 2026-04-13 12:45 | 4.49 (-0.44%) | ||
| Stifel CNS Forum | 2026-03-17 10:00 | 5.48 (+1.48%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-09 08:40 | 4.20 (-6.04%) | ||
| Annual report for 2025 | 2026-03-05 | 4.08 (+2.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 | 4.08 (+2.00%) | ||
| 44(th) Annual J.P. Morgan Healthcare Conference | 2026-01-14 15:45 | 6.06 (+0.33%) |
Show
Entries
Camp4 Therapeutics Corp Frequently Asked Questions
What is Camp4 Therapeutics Corp(CAMP)'s stock price today?
The current price of CAMP is $4.49. The 52 week high of CAMP is $7.75 and 52 week low is $1.41.
When is next earnings date of Camp4 Therapeutics Corp(CAMP)?
The next earnings date of Camp4 Therapeutics Corp(CAMP) is 2026-11-06 Est..
Does Camp4 Therapeutics Corp(CAMP) pay dividends? If so, how much?
Camp4 Therapeutics Corp(CAMP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Camp4 Therapeutics Corp
Headlines
See More- 1
Aug 13, 2026
Camp4 Therapeutics GAAP EPS of -$0.58 misses by $0.37
Seeking Alpha • 4:09pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers